[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-scars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-scars":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,79,108,144,172,202,230,256],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100642037","co2-ladd-tac-with-and-without-5-fu-for-hypertrophic-burn-scars-a-triple-blinded-split-scar-rct-100642037",false,"NCT07660120","CO2 LADD TAC With and Without 5-FU for Hypertrophic Burn Scars: A Triple-Blinded, Split Scar RCT","Comparing the Safety and Efficacy of CO2 Laser-Assisted Triamcinolone Delivery With and Without 5-Fluorouracil for Hypertrophic Burn Scars: A Triple-Blinded, Randomized Split Scar Clinical Trial","Inclusion Criteria:\n\n* Patient with hypertrophic scarring secondary to burn injury\n* Ages 18-89\n\nExclusion Criteria:\n\n* Pregnant patients or patients of childbearing age, sexually active, and unwilling to utilize contraception\n* Children\n* Individuals that are cognitively impaired and unable to provide consent\n* Currently breastfeeding\n* Has taken oral retinoids within 6 months of study initiation\n* Prior laser or intralesional TAC\u002F5-FU treatments for their hypertrophic scars\n* Active infection\n* Active malignancy\n* Known hypersensitivity to CO2 laser, TAC, or 5-FU\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency (complete or partial), due to risk of systemic 5-FU toxicity\n* Systemic corticosteroid or immunosuppressive medication use\n* Intolerance to anesthesia\n* Known connective tissue disease","ALL","18 Years","89 Years",{"count":20,"type":21},65,"ESTIMATED","INTERVENTIONAL",[24],"NA","Burn scars can sometimes heal in a way that causes them to become thick, raised, and stiff. These scars may itch, feel uncomfortable, limit movement, and affect how the skin looks. Because of this, many burn survivors look for treatments that can help improve both the appearance and the symptoms of their scars.\n\nOne treatment that has shown promise is fractional CO₂ laser therapy. This laser creates tiny openings in the scar tissue that help soften the scar and stimulate the skin to remodel itself. These openings can also help medications applied to the skin reach deeper into the scar where they may work better.\n\nA steroid medication called triamcinolone is commonly used to treat these scars. Another medication, called 5-fluorouracil (5-FU), has been shown in prior studies to work well when combined with steroids, but it is usually given by injection, which can be painful and sometimes causes side effects.\n\nIn this study, we will look at whether delivering these medications through the laser openings can improve scars more effectively. Each participant's scar will be divided into two halves. One side will receive both medications, and the other side will receive the steroid alone. By comparing the two sides of the same scar, we hope to better understand whether adding 5-FU provides additional benefit.",[27,28,29,30],"Burn","Hypertrophic Scars","Scar Improvement by Laser","CO2 Laser in Scars",[32,33,34,35],"burn scar","hypertrophic scar","CO2 Laser","laser assisted drug delivery","NOT_YET_RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":39,"type":21},{"date":43,"type":21},"2028-07-10",{"name":45,"class":46},"University of California, Davis","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100618803","phase-3-topical-cryotherapy-and-keloidhypertrophic-scars-100618803","NCT07336368","Topical Cryotherapy and Keloid\u002FHypertrophic Scars","Topical Cryotherapy to Reduce Pain During Steroid Injections for Keloid and Hypertrophic Scars: A Pilot Study","Inclusion Criteria:\n\n* Adults (≥18 years) with keloids or hypertrophic scars already scheduled to receive intralesional triamcinolone (TAC) as part of routine care.\n* At least one keloid or hypertrophic scar with two comparable regions (≥2 cm each) suitable for split-treatment.\n* Able to provide informed consent and complete pain assessments in English.\n\nExclusion Criteria:\n\n* Keloid or hypertrophic scar located on the face (except earlobes), excluded for cosmetic reasons.\n* Prior treatment to the study-selected keloid\u002Fhypertrophic scar based on self-report.\n* Inability to complete study assessments due to cognitive or language barriers.",{"count":55,"type":21},30,[57],"PHASE3","The goal of this clinical trial is to determine whether the application of brief topical cryotherapy immediately before intralesional corticosteroid injections can reduce pain and injection resistance during routine treatment of keloid and hypertrophic scars in adult patients.\n\nThe main questions it aims to answer are:\n\nDoes topical cryotherapy applied before intralesional triamcinolone injection impact pain perceptions for participants with keloids or hypertrophic scars?\n\nDoes topical cryotherapy affect provider-assessed injection resistance compared with standard injection alone?\n\nResearchers will split the keloid\u002Fhypertrophic scar into two halves. One half will be treated with cryotherapy followed by steroid injection, while the other half will be treated with steroid injection alone to evaluate differences in pain perception and injection resistance.\n\nParticipants will rate pain after each injection using a 10-point numeric pain scale. Clinicians will rate the resistance after each injection using a 10-point numeric scale.",[60,28],"Keloid Scars",[62,63,64,65,66,67,68],"Keloid scars","Hypertrophic scars","Cryotherapy","Intralesional corticosteroids","Pain reduction","Injection resistance","Injection pain","RECRUITING","2026-06-10",{"date":72,"type":40},"2026-06-12",{"date":70,"type":40},{"date":75,"type":21},"2027-08",{"name":77,"class":46},"Sonal Choudhary",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100635806","nano-fat-grafting-for-post-burn-scars-on-the-chest-shoulders-and-back-100635806","NCT07557472","Nano-Fat Grafting for Post-Burn Scars on the Chest, Shoulders, and Back","Evaluation of Nano-Fat Grafting in Post-Burn Hypertrophic Scars at Chest, Shoulders, and Back","Inclusion Criteria:\n\n* Age 18 to 50 years.\n* Presence of post-burn hypertrophic scars located on the chest, shoulders, or back.\n* Age of the scar is less than 6 months.\n\nExclusion Criteria:\n\n* Active infection or ulceration at the site of the scar.\n* Patients with systemic connective tissue diseases or bleeding disorders.\n* Hypertrophic scars older than 6 months.\n* History of keloids or previous surgical excision of the same scar.\n* Previous corticosteroid injections into the scar.\n* Pregnancy and lactation.\n* Refusal to undergo surgery.","50 Years",{"count":88,"type":21},55,[24],"This study aims to evaluate the effectiveness of nano-fat grafting in treating hypertrophic scars caused by burns on the chest, shoulders, and back.\n\nBurn scars in these specific areas are often difficult to treat because the skin is under constant tension and motion, which can prolong inflammation and worsen the scar. While conventional scar treatments like silicone patches, pressure garments, and steroid injections are widely used, they do not always completely restore normal tissue. Nano-fat grafting is emerging as a promising regenerative option. This procedure involves taking a small amount of the patient's own fat and processing it into a liquid that is rich in healing cells. This liquid is then injected directly into the scar to potentially improve skin texture, color, and flexibility.\n\nThe study will enroll 55 participants between the ages of 18 and 50. To be eligible, patients must have a post-burn hypertrophic scar on their chest, shoulder, or back that is less than 6 months old.\n\nDuring the study, doctors will harvest a small amount of fat from the patient's abdomen or thighs using a small tube. This fat will be carefully washed, processed, and passed through a special filter to create liquid nano-fat. The liquid is then gently injected into the scar tissue.\n\nResearchers will monitor the patients and evaluate the scars at 1, 3, and 6 months after the injection. They will use standard clinical scar assessments (the Vancouver Scar Scale and the Patient and Observer Scar Assessment Scale) alongside photographs to measure improvements in scar color, thickness, pliability, and overall appearance, as well as patient-reported symptoms like pain and itching.",[28,92,93],"Post-burn Scars","Burns",[95,96,97,98],"Nano-fat Grafting","Fat Grafting","Scar Rejuvenation","Autologous Fat Injection","2026-04-23",{"date":101,"type":40},"2026-04-29",{"date":103,"type":21},"2026-06",{"date":105,"type":21},"2027-07",{"name":107,"class":46},"Assiut University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100620571","surgical-care-and-recovery-with-laser-evaluation-trial-scarlet-100620571","NCT07359352","Surgical Care And Recovery With Laser Evaluation Trial (SCARLET)","SCARLET","Inclusion Criteria:\n\nAdults aged 18 years or older.\n\nScheduled to undergo one or more of the following major body-contouring procedures during the study period:\n\nBrachioplasty (arm lift)\n\nChest or breast contouring surgery\n\nAbdominoplasty or panniculectomy\n\nButtock lift or lower body lift\n\nThighplasty (thigh lift)\n\nAble and willing to provide written informed consent.\n\nAble to read and write in English (required for completion of validated questionnaires).\n\nWilling and able to comply with scheduled follow-up visits, questionnaires, and study procedures for up to 12 months post-surgery.\n\nExclusion Criteria:\n\nInability or unwillingness to provide informed consent.\n\nInability to comply with study visits or procedures.\n\nNon-English speakers, as the validated SCAR-Q and POSAS instruments are not currently available in equivalent translations.\n\nCurrent use of nicotine or nicotine-containing products, including cigarettes, vaping, chewing tobacco, or nicotine replacement therapy, due to the known adverse effects of nicotine on wound healing and scar formation.\n\nAny medical condition, treatment, or circumstance that, in the opinion of the Investigator, may increase participant risk, compromise safety, or interfere with study participation or data integrity.\n\nPregnant or breastfeeding women (laser\u002FBBL therapy contraindicated in pregnancy).\n\nHistory of abnormal scar formation such as keloids or hypertrophic scarring (if deemed clinically significant by the investigator).\n\nRecent energy-based treatment (laser, IPL, or BBL) to the surgical site within the previous 3 months.",true,{"count":117,"type":21},150,[24],"The Surgical Care and Recovery with Laser Evaluation Trial (S.C.A.R.L.E.T.) is a prospective, single-center clinical study conducted at AdventHealth Medical Group Plastic and Reconstructive Surgery at Innovation Tower. The study evaluates whether early adjuvant ProFractional laser and\u002For Broadband Light (BBL) therapy improves the appearance, texture, and patient-reported outcomes of surgical scars following major body-contouring procedures. Participants undergoing qualifying surgeries will be grouped as either cosmetic (receiving three laser\u002FBBL sessions) or non-cosmetic (receiving standard care only). Scar outcomes will be assessed using validated instruments-SCAR-Q and Patient and Observer Scar Assessment Scale (POSAS)-along with standardized photographic analysis at serial follow-ups through six months postoperatively.",[121,28,122,123,124],"Post-surgical Scars","Scar Appearance Dissatisfaction","Aesthetic Surgical Outcomes","Wound Healing After Body-contouring Surgery",[126,127,128,129,130,131,132,133,134],"Surgical scar","Postoperative scar","Hypertrophic scar","Body-contouring surgery","Abdominoplasty scar","Brachioplasty scar","Thighplasty scar","Scar revision","Laser-assisted scar remodeling","2026-01-14",{"date":137,"type":40},"2026-01-22",{"date":139,"type":21},"2026-04-01",{"date":141,"type":21},"2027-10-01",{"name":143,"class":46},"AdventHealth",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100613630","efficacy-in-preventing-hypertrophic-scars-a-randomised-controlled-trial-comparing-chitosan-cream-silicone-gel--olive-oil-100613630","NCT07269093","Efficacy in Preventing Hypertrophic Scars: A Randomised Controlled Trial Comparing Chitosan Cream, Silicone Gel & Olive Oil","Inclusion Criteria:\n\n* Patients with traumatic or surgical wounds which have healed by primary intention within 14 days\n* Length of scar at least 3cm\n\nExclusion Criteria:\n\n* Patients with seafood allergy\n* Patients with scar from wounds that were complicated by infection or wound breakdown\n* Patients who have undergone scar treatment by other modalities\n* Patients with history of keloids \u002F hypertrophic scars\n* Pregnant patients","65 Years",{"count":152,"type":21},120,[24],"The goal of this clinical trial is to compare the efficacy of three different topical applications in preventing hypertrophic scars in adults with scars healed after suturing. The main question it aims to answer is: Is Chitosan cream effective in preventing hypertrophic scars?\n\nResearchers will compare Chitosan cream with silicone gel and olive oil to see if there is any difference in their efficacies.\n\nParticipants will be randomly assigned to three groups, with each group using a different topical application. They will be instructed to:\n\n* apply the topical application on their scar twice a day for 8 weeks\n* attend follow-up visits at 4, 12 and 24 weeks for a doctor to assess their scar and take clinical photographs\n* immediately inform the researcher if they experience any side effects",[28],[157,158,159,160,161],"Chitosan","silicone gel","olive oil","hypertrophic scars","prevention","2025-12-28",{"date":164,"type":40},"2026-01-02",{"date":166,"type":40},"2025-12-21",{"date":168,"type":21},"2026-11",{"name":170,"class":46},"Universiti Sains Malaysia",3,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":201},"100573834","phase-1-evaluation-of-clinical-perceived-and-instrumental-efficacy-of-a-scar-gel-in-preventing-hypertrophic-scars-100573834","NCT06751433","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel Versus Benchmark in Preventing Hypertrophic Scars and Improving Scar Appearance","Inclusion Criteria:\n\n1. Participants of both sexes aged between 18 and 70 years;\n2. Participants with recent scars (\\\u003C30 days);\n3. Participants with phototypes III to VI according to the Fitzpatrick scale;\n4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations;\n5. Understand, agree to and sign the free and informed consent form.\n6. Types of scars: cesarean section, breast implant or blunt cut injury.\n\nExclusion Criteria:\n\n1. Pregnancy or risk of pregnancy;\n2. History of atopic or allergic reactions to cosmetic products;\n3. Participants who are using topical antibiotics or other skin products on the same area being evaluated;\n4. Immunosuppression due to drugs or active diseases;\n5. Decompensated endocrine diseases;\n6. Relevant clinical history or current evidence of alcohol or other drug abuse;\n7. Known history or suspected intolerance to products in the same category;\n8. Intense sun exposure up to 15 days before the evaluation;\n9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.","70 Years",{"count":181,"type":21},80,[183,184],"PHASE1","PHASE2","Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.",[187,188,189,190,28,60],"Acceptability Study","Real-use Conditions","Safety and Efficacy","Topical Administration","2025-09-09",{"date":193,"type":40},"2025-09-11",{"date":195,"type":40},"2025-04-03",{"date":197,"type":21},"2025-12",{"name":199,"class":200},"Herbarium Laboratorio Botanico Ltda","INDUSTRY",2,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100575112","microporous-tape-and-post-surgical-scars-100575112","NCT06768047","Microporous Tape and Post Surgical Scars","Inclusion Criteria:\n\n1. The patients' age will range from 20-45 years, and will be selected from both genders .\n2. All patients will have hypertrophic scars after surgeries.\n3. The general size of the scars will range from 5 to 7 cm'2\n\nExclusion Criteria:\n\n1. The patients who will excluded from the study including those with infected post-operative wounds .\n2. The patients whose wounds were closed secondarily or healed by secondary intention.\n3. patients who are keloid formers.\n4. Uncontrolled diabetes mellitus\n5. Uncontrolled hypertension.\n6. The patients who had a deep venous thrombosis (DVT).\n7. Hypersensitivity reaction to Microporous tape.","20 Years","45 Years",{"count":211,"type":21},44,[24],"The aim of this study is to determine the effect of microporous taping on improving scar characteristics in post-surgical HTS.",[215,28],"Microporous Tape",[217,218,219,220],"Microporous tape","Post surgical hypertrophic scars","Modified Vancouver Scar Scale","Schiotz tonometer.","2025-01-06",{"date":223,"type":40},"2025-01-10",{"date":225,"type":21},"2025-01-07",{"date":227,"type":21},"2025-03-07",{"name":229,"class":46},"Cairo University",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100567137","early-phase-1-effect-of-prf--fractional-co2-laser-in-postburn-hypertrophic-scars-100567137","NCT06664268","Effect of PRF & Fractional CO2 Laser in Postburn Hypertrophic Scars","Clinical and Ultrasound Assessment of Efficacy of Plasma Rich Fibrin (PRF) Injection and Fractional CO2 Laser in Treatment of Postburn Hypertrophic Scars: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients aged from 18 to 60 years\n* Mature post burn scars (more than 6 months).\n* Scar area does not exceed 5% of body surface area (TBSA).\n\nExclusion Criteria:\n\n* Immature scars (less than 6 months).\n* Large scar area (more than 5%of body surface area (TBSA).\n* Previous scar treatment with other modalities.\n* Keloid scars.","60 Years",{"count":55,"type":21},[240],"EARLY_PHASE1","Recent advancements in scar management include the use of Plasma Rich Fibrin (PRF) injections and fractional CO2 laser treatments. Both modalities are considered innovative approaches that offer promising outcomes in scar revision .\n\nPlasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. Unlike platelet-rich plasma (PRP), PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines . This matrix has been shown to enhance wound healing and improve scar texture and appearance. Studies have demonstrated PRF's efficacy in treating various skin conditions, including acne scars and general skin rejuvenation, suggesting potential benefits for postburn scar management .\n\nFractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues . Clinical trials have validated the effectiveness of fractional CO2 lasers in reducing scar thickness and improving skin texture, making it a popular choice for scar revision .",[28,243],"Burn Scar Patients",[245,246,247],"PRF","Fractional CO2 Laser","Postburn Hypertrophic Scars","2024-10-28",{"date":250,"type":40},"2024-10-29",{"date":252,"type":21},"2024-11-01",{"date":254,"type":21},"2025-12-01",{"name":107,"class":46},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":78},"100565977","electromotive-drug-administration-of-magnesium-sulphate-on-hypertrophic-scar-100565977","NCT06649188","Electromotive Drug Administration of Magnesium Sulphate on Hypertrophic Scar","Electromotive Drug Administration of Magnesium Sulphate on Hypertrophic Scar Post-Burn","Inclusion Criteria:\n\n* 1-Patient with hypertrophic scar (3-6) months after burn healing. 2-Age range between 20-40 years. 3-Male and female patients will participate in the study. 4-All patients have a post-burn hypertrophic scar at different body sites. 5-All patients enrolled on the study will have their informed consent.\n\nExclusion Criteria:\n\n\\- 1-Patients with prior medical histories of cardiac arrhythmias. 2-Patients with cardiac pacemakers. 3-Patients with orthopaedic implants. 4-Areas of skin with lesions and impaired sensation. 5-During pregnancy and breastfeeding. 6-Patient with diabetes mellitus. 7-Patients with a history of hypersensitivity or adverse reactions associated with (MgSO4).\n\n8-Recent MgSO4 administration 6 months before the study. 9-Any subject complaining of psychiatric disorders or neurological disorders such as myasthenia gravis","40 Years",{"count":181,"type":21},[24],"In this study 80 patients will be randomly assigned into two equal groups (40 patients for each group):\n\n1. Group A: Experimental: Magnesium Sulphate Iontophoresis for Postburn Hypertrophic Scar The study group includes 40 postburn hypertrophic scar patients will receive Magnesium Sulphate iontophoresis twice a week for 4 weeks; in addition to their traditional physical therapy program (deep friction massage, stretching and pressure therapy).\n2. Group B: Control: Traditional physical therapy for postburn hypertrophic scar This group includes 40 patients with postburn hypertrophic scar who will receive only the traditional PT (deep friction massage, stretching and pressure therapy) 2 sessions per week for 4 weeks",[28],[269,270],"Iontophoresis","Post burn","2024-10-17",{"date":273,"type":40},"2024-10-18",{"date":275,"type":21},"2024-11-15",{"date":277,"type":21},"2025-01-15",{"name":229,"class":46}]